Methotrexate Sodium in Psoriasis vulgaris: CTRI/2026/03/107054 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Not Yet Recruiting
Recruitment status
58
Planned enrollment
Timing not reported
Primary-completion proxy
Executive view
CTRI/2026/03/107054 evaluates Methotrexate Sodium in Psoriasis vulgaris. The disclosed sponsor is Kims Hospital Ltd., the design is Interventional, and the geographic footprint is India. The first listed primary endpoint is not reported, assessed over an unreported time frame.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for CTRI/2026/03/107054 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Psoriasis vulgaris landscape. Drug & Asset MCP drug_fetch was queried for Methotrexate Sodium, while Company & Deal Intelligence MCP organization_fetch was queried for Kims Hospital Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| CTRI/2026/03/107054 | Methotrexate Sodium | Phase 2 / Not Yet Recruiting | Kims Hospital Ltd. | India | Timing not reported | |
| NCT07581418 | Tofacitinib Citrate | Not Applicable / Not yet recruiting | Sponsor not reported | Geography not reported | Change in Psoriasis Area and Severity Index (PASI) score 8 weeks | 2026-12-01 |
| ISRCTN91905052 | Ixekizumab | Not Applicable / Recruiting | Guangdong Hospital of Traditional Chinese Medicine | China | Primary endpoint not reported Time frame not reported | 2028-12-31 |
| CTRI/2026/04/109640 | Apremilast | Not Applicable / Not Yet Recruiting | Sponsor not reported | India | Timing not reported | |
| NCT07546214 | Tapinarof | Phase 1 / Completed | Sun Pharmaceutical Industries Ltd. | United States | Demonstration in Therapeutic Equivalence & Safety of the Investigational Product Baseline to Week 12 | 2026-03-18 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
CTRI/2026/03/107054 is a Phase 2, not yet recruiting study with 58 planned participants. Allocation is not reported, masking is not reported, and the intervention model is not reported.
The primary endpoint is “not reported” over “not reported.” The retrieved endpoint description is: PASI scoring evaluatedTimepoint: week 0 week 4 week 8 week 12.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 58 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Psoriasis vulgaris. These records do not establish direct evidence for CTRI/2026/03/107054 unless the registration number matches.
Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study
Phase 4; n=101; PASI75(24-week) = 77.2 % Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/41769731/
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis
Phase 3; n=337; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 26.1 percentage of participants ; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 33.3 percentage of participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04286607
Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase…
Phase 3; n=502; Adverse Event: nasopharyngitis = The most common treatment-emergent adverse events were upper respiratory tract infections and nasopharyngitis. Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42372782/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Methotrexate Sodium is indexed as Small molecule drug with DHFR biology and a global stage of Approved. The asset profile lists Endo International Plc as an originator or developer.
Kims Hospital Ltd. is indexed in United Kingdom with the website http://www.kims.org.uk. KIMS Hospital is the largest independent hospital in Kent providing prompt, safe, quality care for our patients. The record lists an unreported number of development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Methotrexate Sodium is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: CTRI/2026/03/107054
Protocol source: http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=158927
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
Methotrexate Sodium in Psoriasis vulgaris is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the primary endpoint and Timing not reported the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
